JP2015522806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522806A5 JP2015522806A5 JP2015516071A JP2015516071A JP2015522806A5 JP 2015522806 A5 JP2015522806 A5 JP 2015522806A5 JP 2015516071 A JP2015516071 A JP 2015516071A JP 2015516071 A JP2015516071 A JP 2015516071A JP 2015522806 A5 JP2015522806 A5 JP 2015522806A5
- Authority
- JP
- Japan
- Prior art keywords
- glyca
- nmr
- component
- region
- nmr spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 26
- 238000005481 NMR spectroscopy Methods 0.000 claims 14
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 11
- 238000005259 measurement Methods 0.000 claims 10
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 7
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 7
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 7
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 7
- 239000004474 valine Substances 0.000 claims 7
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 108010004103 Chylomicrons Proteins 0.000 claims 3
- 102000004895 Lipoproteins Human genes 0.000 claims 3
- 108090001030 Lipoproteins Proteins 0.000 claims 3
- 238000004891 communication Methods 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 238000004590 computer program Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 239000012491 analyte Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657315P | 2012-06-08 | 2012-06-08 | |
| US61/657,315 | 2012-06-08 | ||
| US201261711471P | 2012-10-09 | 2012-10-09 | |
| US61/711,471 | 2012-10-09 | ||
| US201261739305P | 2012-12-19 | 2012-12-19 | |
| US61/739,305 | 2012-12-19 | ||
| US13/830,199 US9470771B2 (en) | 2012-06-08 | 2013-03-14 | NMR measurements of NMR biomarker GlycA |
| US13/830,199 | 2013-03-14 | ||
| PCT/US2013/043343 WO2013184483A1 (en) | 2012-06-08 | 2013-05-30 | Nmr measurements of glyca |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522806A JP2015522806A (ja) | 2015-08-06 |
| JP2015522806A5 true JP2015522806A5 (enExample) | 2016-06-16 |
| JP6177899B2 JP6177899B2 (ja) | 2017-08-09 |
Family
ID=49712504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516071A Active JP6177899B2 (ja) | 2012-06-08 | 2013-05-30 | ＧｌｙｃＡのＮＭＲ測定 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9470771B2 (enExample) |
| EP (3) | EP4439587A3 (enExample) |
| JP (1) | JP6177899B2 (enExample) |
| CN (1) | CN104508471B (enExample) |
| AU (1) | AU2013272014B2 (enExample) |
| CA (2) | CA3146947A1 (enExample) |
| FI (1) | FI3839544T3 (enExample) |
| SG (1) | SG11201407803TA (enExample) |
| WO (1) | WO2013184483A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9076342B2 (en) | 2008-02-19 | 2015-07-07 | Architecture Technology Corporation | Automated execution and evaluation of network-based training exercises |
| US9928345B2 (en) * | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US20140358451A1 (en) * | 2013-06-04 | 2014-12-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Fractional Abundance Estimation from Electrospray Ionization Time-of-Flight Mass Spectrum |
| CN106415276B (zh) * | 2013-11-27 | 2018-10-16 | 威尔吉利健康研究所 | 用于表征脂蛋白的方法 |
| EP3058369B1 (en) * | 2014-01-06 | 2020-06-17 | Liposcience, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| CN107110939B (zh) * | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| JP6442053B2 (ja) | 2014-10-31 | 2018-12-19 | 華為技術有限公司Ｈｕａｗｅｉ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏ．，Ｌｔｄ． | 曲線当てはめ回路、アナログ前置補償器、および無線周波数信号送信器 |
| US10803766B1 (en) | 2015-07-28 | 2020-10-13 | Architecture Technology Corporation | Modular training of network-based training exercises |
| US10083624B2 (en) | 2015-07-28 | 2018-09-25 | Architecture Technology Corporation | Real-time monitoring of network-based training exercises |
| EP3258285B1 (en) * | 2016-06-14 | 2020-10-21 | Bruker BioSpin GmbH | Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid |
| DE102016224691A1 (de) * | 2016-12-12 | 2018-06-14 | Numares Ag | Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe |
| FI20177098A1 (fi) * | 2017-08-29 | 2019-03-01 | Leppaeluoto Juhani | Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen |
| WO2019051226A1 (en) | 2017-09-07 | 2019-03-14 | Liposcience, Inc. | METABOLIC VULNERABILITY INDEX ASSESSMENTS WITH MULTIPLE PARAMETERS |
| CN107796946B (zh) * | 2017-10-20 | 2019-10-25 | 中国医学科学院基础医学研究所 | 尿液中冠心病的蛋白标志物及其用途 |
| WO2019094879A1 (en) * | 2017-11-10 | 2019-05-16 | Liposcience, Inc. | Methods and systems to detect and quantify the amount of lp-x and other abnormal lipoproteins in a biosample using nmr spectroscopy |
| WO2019143801A1 (en) * | 2018-01-18 | 2019-07-25 | New York University | System and method for blood glucose monitoring using magnetic resonance spectroscopy |
| CN109805898B (zh) * | 2019-03-22 | 2024-04-05 | 中国科学院重庆绿色智能技术研究院 | 基于注意力机制时序卷积网络算法的危重症死亡预测方法 |
| US11887505B1 (en) | 2019-04-24 | 2024-01-30 | Architecture Technology Corporation | System for deploying and monitoring network-based training exercises |
| EP4281768A1 (en) * | 2021-01-22 | 2023-11-29 | Bruker BioSpin MRI GmbH | Infection diagnosis and characterization using diffusion and relaxation edited proton nmr spectroscopy |
| US20240044826A1 (en) * | 2022-08-05 | 2024-02-08 | Liposcience, Inc. | Metabolic vulnerability analyzed by nmr |
| DE102023110285B3 (de) | 2023-04-21 | 2024-05-08 | Universität zu Lübeck, Körperschaft des öffentlichen Rechts | Nmr-messung von glykoproteinen |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529710A (en) | 1981-06-12 | 1985-07-16 | The United States Of America As Represented By The United States Department Of Energy | Method of using a nuclear magnetic resonance spectroscopy standard |
| JPH0698036B2 (ja) | 1986-10-20 | 1994-12-07 | 小野薬品工業株式会社 | アミノ酸の選択的定量法 |
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| WO2000051054A1 (en) | 1999-02-26 | 2000-08-31 | Lipomed, Inc. | Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood |
| US6653140B2 (en) * | 1999-02-26 | 2003-11-25 | Liposcience, Inc. | Methods for providing personalized lipoprotein-based risk assessments |
| CA2367820C (en) | 1999-04-22 | 2009-12-22 | James D. Otvos | Nmr-method for determining the risk of developing type 2 diabetes |
| CA2331116A1 (en) | 2001-01-15 | 2002-07-15 | Chenomx, Inc. | Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system |
| WO2003012416A1 (en) | 2001-08-01 | 2003-02-13 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein x in blood plasma and serum |
| WO2003107270A2 (en) | 2002-06-14 | 2003-12-24 | Pfizer Limited | Metabolic phenotyping |
| US7243030B2 (en) | 2002-10-25 | 2007-07-10 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| WO2004085996A2 (en) | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
| CA2542107A1 (en) | 2003-10-23 | 2005-05-12 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size |
| AU2005230449B2 (en) | 2004-04-01 | 2010-02-18 | Liposcience, Inc. | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
| WO2006057081A1 (en) | 2004-11-24 | 2006-06-01 | Mitsuyo Okazaki | Method for analyzing lipoproteins |
| JP5006524B2 (ja) | 2005-05-13 | 2012-08-22 | 株式会社日立製作所 | 緩和時間特定のためのｎｍｒ装置の信号処理方法 |
| JP4358814B2 (ja) | 2005-11-09 | 2009-11-04 | 花王株式会社 | 試料の解析方法 |
| DE602007011592D1 (de) | 2006-03-24 | 2011-02-10 | Metanomics Gmbh | MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II |
| WO2007133593A2 (en) | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
| WO2008137075A2 (en) | 2007-05-02 | 2008-11-13 | President And Fellows Of Harvard College | Compositions and methods for the treatment of metabolic disorders and inflammation |
| US7923257B2 (en) | 2007-05-04 | 2011-04-12 | Perkinelmer Health Sciences, Inc. | Detecting isomers using differential derivatization mass spectrometry |
| EP2019311A1 (en) | 2007-07-23 | 2009-01-28 | F.Hoffmann-La Roche Ag | A method for detecting a target substance by nuclear magnetic resonance |
| WO2010005982A2 (en) | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| EP2344890B1 (en) | 2008-10-20 | 2021-08-11 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods |
| WO2010114897A1 (en) | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| US8741788B2 (en) | 2009-08-06 | 2014-06-03 | Applied Materials, Inc. | Formation of silicon oxide using non-carbon flowable CVD processes |
| US7935643B2 (en) | 2009-08-06 | 2011-05-03 | Applied Materials, Inc. | Stress management for tensile films |
| US8449942B2 (en) | 2009-11-12 | 2013-05-28 | Applied Materials, Inc. | Methods of curing non-carbon flowable CVD films |
| US20110136241A1 (en) | 2009-12-08 | 2011-06-09 | Stephen Naylor | Type ii diabetes molecular bioprofile and method and system of using the same |
| CN102754193A (zh) | 2010-01-06 | 2012-10-24 | 应用材料公司 | 使用氧化物衬垫的可流动电介质 |
| CA2799757C (en) | 2010-05-21 | 2018-12-04 | The Governors Of The University Of Alberta | Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| CA2887475C (en) | 2012-10-09 | 2021-12-14 | Liposcience, Inc. | Nmr quantification of branched chain amino acids |
-
2013
- 2013-03-14 US US13/830,199 patent/US9470771B2/en active Active
- 2013-05-30 CN CN201380041876.4A patent/CN104508471B/zh active Active
- 2013-05-30 JP JP2015516071A patent/JP6177899B2/ja active Active
- 2013-05-30 EP EP24189279.3A patent/EP4439587A3/en active Pending
- 2013-05-30 CA CA3146947A patent/CA3146947A1/en active Pending
- 2013-05-30 EP EP13800239.9A patent/EP2859339B1/en active Active
- 2013-05-30 WO PCT/US2013/043343 patent/WO2013184483A1/en not_active Ceased
- 2013-05-30 AU AU2013272014A patent/AU2013272014B2/en active Active
- 2013-05-30 CA CA2874550A patent/CA2874550C/en active Active
- 2013-05-30 FI FIEP20199970.3T patent/FI3839544T3/fi active
- 2013-05-30 EP EP20199970.3A patent/EP3839544B1/en active Active
- 2013-05-30 SG SG11201407803TA patent/SG11201407803TA/en unknown
-
2016
- 2016-09-14 US US15/264,977 patent/US10852293B2/en active Active
-
2020
- 2020-11-13 US US17/097,640 patent/US11692995B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522806A5 (enExample) | ||
| US12270780B2 (en) | Systems and methods for electrochemical hematocrit determination by alternate current impedance phase angle determinations | |
| CN104520699B (zh) | 多参数糖尿病风险评价 | |
| JP6177899B2 (ja) | ＧｌｙｃＡのＮＭＲ測定 | |
| Desimoni et al. | About estimating the limit of detection by the signal to noise approach | |
| JP2015524917A5 (enExample) | ||
| Hammarsten et al. | Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction | |
| Ellis et al. | Reproducibility of human cardiac phosphorus MRS (31P‐MRS) at 7 T | |
| RU2017131046A (ru) | Способы и системы для калибровки биологического прибора | |
| Wang et al. | Coefficient of variation, signal-to-noise ratio, and effects of normalization in validation of biomarkers from NMR-based metabonomics studies | |
| Craven et al. | Comparison of seven modelling algorithms for γ‐aminobutyric acid–edited proton magnetic resonance spectroscopy | |
| Schmitt et al. | The dynamic associations between cortical thickness and general intelligence are genetically mediated | |
| Birch et al. | Influence of macromolecule baseline on 1H MR spectroscopic imaging reproducibility | |
| Mosconi et al. | Different quantification algorithms may lead to different results: a comparison using proton MRS lipid signals | |
| JP2007511749A (ja) | 個別サイズのｌｄｌ（低比重リポ蛋白）サブクラス粒子の生体内での濃度勾配を考慮する数理モデルを使用してｃｈｄ（冠状動脈性心臓疾患）のリスクを評価する方法、システムおよびコンピュータプログラム | |
| Hoch et al. | When are metabolic ratios superior to absolute quantification? A statistical analysis | |
| JP5945365B2 (ja) | Ｎｍｒスペクトルから物質を同定するための方法 | |
| JP2013024881A5 (enExample) | ||
| JP2017532548A (ja) | Ｈｄｌおよび炎症性バイオマーカインタラクションパラメータを含むリスクパラメータを用いた心血管リスク評価 | |
| Candemir | A Practical Estimation of the Required Sample Size in fMRI Studies | |
| Pilgrim‐Morris et al. | Mapping the amplitude and phase of dissolved 129Xe red blood cell signal oscillations with keyhole spectroscopic lung imaging | |
| Schubert et al. | Towards a neurochemical profile of the amygdala using short‐TE 1H magnetic resonance spectroscopy at 3 T | |
| Sordoń et al. | Voltammetric determination of caffeic, syringic and vanillic acids taking into account uncertainties in both axes | |
| CN112305246A (zh) | 样本分析方法及样本分析系统 | |
| Hazan et al. | Practical application of Alzheimer's Disease Neuroimaging Initiative plasma P‐tau181 reference data to support diagnosis of Alzheimer's disease |